Healthcare
RESEARCH NOTE #016

It Reached a Tumor. Can It Treat It? PeptiDream's Next Test

Published Nov. 5, 2026 · About 6 min
Investment thesis

Peptide-based radiotherapy is already a real medical treatment. But PeptiDream's own kidney-cancer candidate has yet to prove that it improves outcomes.

In a five-patient imaging study involving clear-cell kidney cancer, PD-32766 accumulated in many tumor lesions. A US Phase 1 study began in July 2026. Can the discovery platform, combined with a large manufacturing investment, deliver a viable therapy and sustainable earnings?

Social valueMore targeted optionsImaging may identify patients for targeted therapy.
Shareholder valueFrom milestones to product revenueAn owned supply chain could create repeat earnings.
Critical testReaching is not treatingEfficacy, approval and factory economics all matter.
Company & ticker
ペプチドリーム株式会社 / PeptiDream Inc. 4587:TYO
Research sections
Background

The method has worked; this particular drug is still experimental

Lutathera, a peptide radiopharmaceutical, was approved by the FDA in 2018 for a defined group of neuroendocrine tumors. It was not developed by PeptiDream.

PD-32766 targets CA9, a marker common in clear-cell kidney cancer, and was studied using copper-64 for imaging. Actinium-225 is being tested for therapy. The clinical outcomes of the first drug cannot be extrapolated to this candidate.

Concept illustration of peptide targeting, copper-64 imaging and actinium-225 therapy
Concept: a peptide finds a tumor marker, copper-64 helps image it, and actinium-225 is investigated for targeted therapy.
Verified facts

What has been demonstrated?

1
Approved peptide therapyLutathera was FDA approved in 2018, though it is unrelated to PeptiDream's own products. Source
2
Five-patient imaging evidenceIn five patients, PET positivity was 96.2% by lesion but averaged 75% at the patient level (120 minutes after injection). These early imaging results do not prove treatment efficacy. Source
3
Phase 1 began in July 2026PD-32766 began a US Phase 1 study. Efficacy remains unproven. Source
4
Antibody competitorTelix uses an antibody against the same CAIX target and was preparing a US resubmission in October 2026. Source
5
¥16.5bn manufacturing planPDR Pharma plans a new Chiba facility for completion in September 2028. Source
6
Current margins remain lowH1 2026 radiopharmaceutical sales were ¥8.03bn with ¥0.24bn segment profit; group operating loss was ¥2.53bn. Source
Our hypothesis

Can a molecule become repeat revenue?

1Discover a peptide that binds a tumor target
2Use diagnostic isotopes to test human tumor uptake
3Prove safety and meaningful efficacy with treatment isotopes
4Produce and distribute approved drugs through PDR Pharma
5Reinvest manufacturing profits and licensing income in new candidates

The possibility is to evolve from volatile licensing milestones to product earnings. But imaging uptake is not a demonstration of therapeutic benefit.

Some current diagnostic products are not derived from PeptiDream's peptide platform.

Research, clinical testing, radiopharmaceutical manufacturing and hospital distribution in a connected process
From discovery to trials, production and hospital delivery: the integrated business PeptiDream is seeking to build.
Risks and disproof

Why the hypothesis might fail

Current status

Uptake observed; efficacy and economics remain to be demonstrated

ConfirmedMethod and early human imaging

An approved peptide therapy exists elsewhere; PD-32766 has entered Phase 1.

PotentialCombined discovery and distribution

Commercialization may generate repeat earnings.

RiskEfficacy and capital returns

A five-patient study does not establish therapeutic benefit.

NextNov. 11 earnings

Review product segment margins and cash flow.

Next tests

Next tests

Nov. 11, 2026Are product margins improving?

Check radio segment earnings and full-year guidance.

Phase 1 updatesWill tumor uptake translate into efficacy?

Separate imaging data, toxicity and outcomes.

2027–2029Will the plant earn a return?

Review approvals, output and financing.

Valuation at writing

What does a ¥145.5bn valuation assume?

Price¥1,119
Market cap~¥145.5bn
Forward P/E~48x
PBR~2.96x
Dividend yield0%
ROENegative

Its discovery capability is credible. Repeatable earnings are not yet proven.

At the Nov. 2, 2026 close of ¥1,119, market capitalization was about ¥145.5bn. Against the company's ¥3bn forecast net profit, that is roughly 48x earnings. The valuation rests on more than today's profits.

PeptiDream's success is not merely a lucky deal: partnerships with Novartis, MSD and other major drug makers have produced development progress and milestone payments. Still, a major agreement helped deliver roughly ¥15bn in net profit in 2024; in 2025, a planned licensing deal was not signed by year-end. Revenue of about ¥18.5bn fell far short of the original ¥49bn forecast, and the company posted a net loss of roughly ¥3.7bn. Repeated scientific progress does not necessarily mean repeatable profits.

Governance remains a concern. A 2025 investigation found that a former deputy executive had removed, or likely removed, up to ¥54m in laboratory reagents without authorization, exposing weaknesses in internal controls. The company announced remedial measures and hired three leaders with operations, strategy and talent-development experience in July 2026. Whether stronger management will translate into effective oversight and earnings remains unproven.

At a hypothetical 25x earnings multiple, sustained net profit of ¥6bn would imply ¥150bn in market value, and ¥10bn would imply ¥250bn. These are simple scenarios, not forecasts; future valuation multiples and share counts may change.

The radiopharmaceuticals business earned only about a 3% segment margin in the first half of 2026. The new plant must ultimately turn approvals and supply capabilities into durable profits.

The ambition to treat cancer in new ways is compelling. But the price already anticipates future commercial success. Further upside requires proof of earnings, not only progress in the lab.

Sources

Worth sharing?Send this research to someone
Published Nov. 5, 2026. Early imaging does not establish treatment efficacy. Market figures use the Nov. 2, 2026 close. This article is not investment advice.